All In MedTech

Device Trial Radar · NCT03519347

Reducing Arrhythmia in Dialysis by Adjusting the Rx Electrolytes/Ultrafiltration, Study A

Radar-A: A Phase 2 Multi-center Study to Evaluate the Safety and Tolerability of Using Point-of-Care-Guided Manipulation of Dialysate Potassium and Dialysate Bicarbonate to Prevent Hemodialysis-Associated Arrhythmias

Last checked: Nov 20, 2026Latest source record: Aug 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

19

Actual

Start

Nov 30, 2018

Primary completion

Jul 12, 2022

Study completion Oct 14, 2022

Sponsor

Lead sponsor
NYU Langone HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Heart, Lung, and Blood Institute (NHLBI); Duke University; National Institutes of Health (NIH)
First posted
May 9, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to test the feasibility of trials which change the dialysate (dialysis bath prescription) of potassium and bicarbonate according to a standardized algorithm and according to the results of blood testing performed prior to each dialysis. In addition, the trial will provide estimates of the extent to which performing dialysis in this way lowers the risk of abnormal heart rhythms in people with kidney failure who are being treated with chronic hemodialysis.

Conditions

  • End Stage Renal Disease

Interventions

  • Potassium Removal MaximizationOther

    This intervention will test whether prioritizing lower potassium dialysate to reduce the incidence of hyperkalemia reduces the incidence of clinically significant arrhythmias compared to an approach minimizing intradialytic fall in serum potassium by using higher potassium dialysates to minimize serum-dialysate potassium gradients. This will be achieved by utilizing an algorithm which couples point-of-care-testing with the choice of one of two dialysate potassium concentrations (2 or 3 mEq/L) that are widely available in dialysis clinics.

  • Potassium Gradient MinimizationOther

    This intervention will test whether minimizing intradialytic fall in serum potassium by using higher potassium dialysates to minimize serum-dialysate potassium gradients reduces the incidence of clinically significant arrhythmias compared to an approach prioritizing lower potassium dialysate to reduce the incidence of hyperkalemia. This will be achieved by utilizing an algorithm which couples point-of-care-testing with the choice of one of two dialysate potassium concentrations (2 or 3 mEq/L) that are widely available in dialysis clinics.

  • Alkalosis AvoidanceOther

    The bicarbonate (HCO3) concentration will be adjusted according to the results of point of care testing of serum chemistries and an algorithm prioritizing alkalosis avoidance by use of lower dialysate HCO3 concentrations.

  • Acidosis avoidanceOther

    The bicarbonate (HCO3) concentration will be adjusted according to the results of point of care testing of serum chemistries and an algorithm prioritizing acidosis avoidance by use of higher dialysate HCO3 concentrations.

  • Point of Care TestingDiagnostic test

    POC testing will use the Abbott BLUE I-STAT CHEM8+ , a portable, handheld device that provides lab quality analysis within 2-3 minutes using a few drops of whole blood (≤100uL).

  • Cardiac MonitorDevice

    Device is one-third of the size of a triple-A battery and is placed subcutaneously in the left chest during a brief procedure that can be done in-office under local anesthesia.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adherence With Proposed InterventionsTime frame: Up to Week 24
  2. Number of Participants Enrolled Per MonthTime frame: Up to Week 24
  3. Proportion of Participants Who Experienced Potassium Intervention-Specific ComplicationsTime frame: Up to Week 24

2 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Duke University School of Medicine

    Durham, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.